UK-based drug delivery company Neurochase has teamed up with Dutch medical technology company VIVOLTA to manufacture electrospun micro-catheters to deliver advanced therapies to the brain.
Neurochase is developing a scalable system to deliver therapies by Convection Enhanced Delivery (CED), directly to specific targets in the brain and the central nervous system CNS.
The British medtech company’s advanced micro-catheter technology allows drugs to pass through the blood-brain barrier to deep brain structures.
It works by generating a pressure gradient at the tip of the catheter, which pushes the drug through the interstitial space, facilitating homogenous distribution and therapeutic effect.
Neurochase CEO Sharon Kane said: “The VIVOLTA relationship has been hugely important in finding a solution to one of the most technically challenging components of the Neurochase delivery system.
“We are excited to be taking our transformative product forward together into large-scale manufacture with such a knowledgeable, skilled and motivated team.”
The current collaboration builds on a 2022 partnership between the two companies to jointly develop the electrospun component of Neurochase’s micro-catheter delivery system.
VIVOLTA worked closely with Neurochase as part of its R&D team, contributing its extensive expertise in material science and application development.
The Dutch company helped enhance the performance of Neurochase’s micro-catheter.
It has now become an exclusive component manufacturer for Neurochase, providing its advanced electrospinning technology and fully automated MediSpin production system.
VIVOLTA CEO Denis Leissing said: “This partnership builds on our already successful product development work with Neurochase, establishing a long-term manufacturing relationship.
“It is a great example of our full suite of electrospinning solutions from product development to commercial manufacturing.
“We’re proud that our team’s expertise along with our unique and scalable MediSpin manufacturing system will help bring this high-performance micro-catheter to patients who will benefit.”
